Novartis Zometa Low, High Doses Have Similar Efficacy - ASCO Study
Executive Summary
Novartis' Zometa 4 mg dose showed similar efficacy to the 8 mg dose in a Phase III study comparing zoledronic acid to Novartis' Aredia in the treatment of tumor-induced hypercalcemia, Pierre Major, MD, McMaster University, said May 21 at the American Society of Clinical Oncology annual meeting in New Orleans.
You may also be interested in...
Novartis Alters Zometa Study Design Due To Renal Function Concerns
Novartis is eliminating the 8 mg Zometa arm of its ongoing bone metastases studies, following the detection of elevated serum creatinine levels in some patients.
Novartis Alters Zometa Study Design Due To Renal Function Concerns
Novartis is eliminating the 8 mg Zometa arm of its ongoing bone metastases studies, following the detection of elevated serum creatinine levels in some patients.
Novartis Aredia Follow-On Zometa Priority Goal Date Set For June
Novartis' bisphosphanate Zometa will receive a priority FDA review for treatment of tumor-induced hypercalcemia. The fast-track review has an estimated user-fee goal date of June 21.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: